Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

• Status: Not yet recruiting
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

For patients with recurrent liver cancer after liver transplantation, the median survival time is low and the prognosis is often poor. On the one hand, it is necessary to take into account the weakened effect of postoperative anti-rejection drugs with the use of immune checkpoint inhibitors, and on the other hand, the therapeutic effect of recurrent tumors should be taken into account. Both HAIC (hepatic arterial infusion chemotherapy) and T+A（Bevacizumab+Atezolizumab) have inhibitory effects on tumor, and we consider combining them organically to explore one that not only has a good inhibitory effect on tumor, but also better reduces the risk and degree of rejection. Therefore, in order to determine the feasibility and effectiveness of hepatic arterial infusion chemotherapy combined with Atezolizumab and Bevacizumab in the second-line treatment of patients with recurrent liver cancer after liver transplantation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hua Li
• Treatments: Atezolizumab; Bevacizumab

Criteria

Inclusion Criteria:

1. Age ≥18 years old, ≤75 years old, gender unlimited;

2. hepatocellular carcinoma confirmed by pathology after liver transplantation;

3. CT and/or MRI confirmed tumor recurrence or metastasis, intrahepatic recurrence and extrahepatic metastasis were not suitable for surgical resection;

4. There is at least one measurable recurrent or metastatic tumor lesion;

5. The expected survival time is more than 3 months;

6. Child-Pugh grade A and B (≤7 points);

7. Function of other vital organs: absolute neutrophil count ≥1.5×10E9/L; Platelet ≥50×10 e9 / L; Hemoglobin ≥9 g/dL; Serum albumin ≥2.8g/dL; Thyroid stimulating hormone (TSH)≤1 ULN(if TSH is abnormal, both T3 and T4 levels should be checked. If the levels of T3 and T4 were normal, the patients could be enrolled); Bilirubin ≤ 1.5x ULN; ALT and AST≤3 times ULN; Serum creatinine ≤1.5 ULN;

8. ECOG scored 0-2 points;

9. The patient fully understands and voluntarily signs the informed consent, and is willing and able to comply with the requirements of visit, treatment plan, laboratory examination and other requirements of the study schedule.

Exclusion Criteria:

1. Positive expression of PD-L1 in immunohistochemical liver biopsy (parenchymal or non-parenchymal cells of liver);

2. Allergic to bevacizumab and Atezolizumab;

3. ≥ grade II myocardial ischemia or myocardial infarction;

4. The hypertensive drugs cannot be controlled to the normal level (systolic blood pressure > 140mmHg, diastolic blood pressure > 90mmHg); Abnormal coagulation function (PT>16s, APTT>43s, TT>21s, Fbg <2g/L), a history of gastrointestinal bleeding within 6 months;

5. Patients with high risk of bleeding or receiving thrombolytic or anticoagulant treatment;

6. Autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis, psoriasis, etc.;

7. The primary liver disease of liver transplantation was autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis;

8. interstitial pneumonia and other lung diseases, poor lung function;

9. Participate in clinical trials of other experimental drugs within 4 weeks;

10. infections requiring systemic treatment;

11. human immunodeficiency virus (HIV) positive infection;

12. Other factors that may affect safety or compliance;

13. During treatment of acute rejection or within 1 month after treatment;

14. Poor compliance.